Welcome to the Autoimmune & Inflammatory Models Summit
Unlocking the Power of Model Translatability for Successful Clinical Trials & Innovative Drug Discovery
In 2025, investment in autoimmune and inflammatory disease R&D is surging, yet 90% of therapies still fail in the clinic due to poor model translatability.
Breakthroughs demand better preclinical tools to predict efficacy, de-risk pipelines, and meet FDA expectations.
Enter: the Autoimmune & Inflammatory Models Summit, the only industry-led meeting uniting pharma and biotech to share cutting-edge case studies on progressing better translatable autoimmune and inflammation models.
Explore how leaders like AbbVie, Pfizer, and Seismic Therapeutics are advancing complex models for target discovery, biomarker validation, and IND success, turning scientific insights into clinical wins.
Meet Our World-Class Speaker Faculty:
Esi Lamouse-Smith
Director - Early Development Translational Medicine in Immunology
Janssen Pharmaceuticals
Today’s breakthrough therapies for autoimmune disease will not come from yesterday’s methodology. I am thrilled to attend a summit where drug discovery experts discuss the latest advances and case studies that exemplify cutting edge translational model systems.
Mark Panzenbeck, Senior Scientist, In Vivo Pharmacology, Bristol Myers Squibb, Expert Speaker